Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCOMPLISH-2: Aleniglipron for Chronic Weight Management in Obesity/Overweight and T2DM
NCT07654374Phase 3Recruiting
- Sponsor
- Gasherbrum Bio
- Start
- Jul 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 3 trial of aleniglipron in obesity, type 2 diabetes mellitus (T2DM), sponsored by Gasherbrum Bio. Started Jul 2026; status: recruiting.
02
Drugs
aleniglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07654374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654374.